Methylnaltrexone: A novel approach for the management of opioid-induced constipation in patients with advanced illness

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 5, 2009, Pages 473-485

  Diego, Laura ^b   Atayee, Rabia ^c   Helmons, Pieter ^d   Von Gunten, Charles F ^a  

^a Institute for Palliative Medicine   (United States)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UCSD MEDICAL CENTER   (United States)

Author keywords

opioid receptor antagonist; Constipation; Laxative; Methylnaltrexone; Opioid; Palliative care; Peripheral opioid antagonist receptor

Indexed keywords

17 METHYLNALTREXONE; 17 METHYLNALTREXONE BROMIDE; ALVIMOPAN; GASTROINTESTINAL AGENT; LACTULOSE; LAXATIVE; LUBRIPROSTONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NKTR 118; OPIATE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANALGESIC ACTIVITY; BODY TEMPERATURE; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEMETHYLATION; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STORAGE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FALLING; FLATULENCE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPOTENSION; ILEUS; INTESTINE MUSCLE; INTESTINE TRANSIT TIME; IRRITABLE COLON; LARGE INTESTINE DISEASE; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; METHADONE TREATMENT; MONOTHERAPY; MYENTERIC PLEXUS; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; OPIOID INDUCED BOWEL DYSFUNCTION; OPIOID INDUCED CONSTIPATION; OPIOID INDUCED EMESIS; ORTHOSTATIC HYPOTENSION; OSMOTIC DIARRHEA; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; POSTOPERATIVE ILEUS; PREGNANCY; PRURITUS; QT INTERVAL; QT PROLONGATION; RECEPTOR AFFINITY; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE TONE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DEFECATION; DRUG APPROVAL; GASTROINTESTINAL MOTILITY; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LAXATIVES; NALTREXONE; NARCOTIC ANTAGONISTS; PALLIATIVE CARE; QUATERNARY AMMONIUM COMPOUNDS; TREATMENT OUTCOME;

EID: 70449727682     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.42     Document Type: Review

References (62)

1. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J. Clin. Oncol. 19, 2542-2554 (2001). (Pubitemid 32391226)
2. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig. Dis. 24, 105-112 (2006).
3. Portenoy RK, Thomas J, Moehl Boatwright ML et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J. Pain Symptom Manage. 35, 458-468 (2008). • Key Phase II clinical trial of interest. (Pubitemid 351601995)
4. Portenoy RK. Constipation in the cancer patient: causes and management. Med. Clin. North Am. 71, 303-311 (1987).
5. Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J. Pain Symptom Manage. 7, 369-371 (1992).
6. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 130, 1480-1491 (2006).
7. Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol. Rev. 40, 121-162 (1988). (Pubitemid 19128262)
8. Collett BJ. Opioid tolerance: the clinical perspective. Br. J. Anaesth. 81, 58-68 (1998).
9. Thomas JR, Von Gunten CF. Management of constipation in patients with cancer. Support Cancer Ther. 2, 47-51 (2004). •• Excellent review on opioid-induced constipation in an advanced-illness population.
10. Cherny NI. The pharmacological management of cancer pain. Eur. J. Cancer. 37(Suppl. 7), S265-S278 (2001).
11. Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy 22, 240-250 (2002).
12. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann. Pharmacother. 41, 984-993 (2007). •• Very good review on the potential of methylnaltrexone.
13. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterology Motil. 16(Suppl. 2), 17-28 (2004).
14. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol. Motil. 17, 643-653 (2005). (Pubitemid 41400712)
15. De Schepper HU, Cremonini F, Park MI et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil. 16, 383-394 (2004). (Pubitemid 39140632)
16. Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J. Pain Symptom Manage. 24, 71-90 (2002).
17. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int. J. Clin. Pract. 61, 1181-1187 (2007). (Pubitemid 46934629)
18. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am. J. Surg. 182, S11-S18 (2001). (Pubitemid 34072942)
19. Berde C, Nurko S. Opioid side effects - mechanism-based therapy. N. Engl. J. Med. 358, 2400-2402 (2008). (Pubitemid 351749167)
20. Miles CL, Fellowes D, Goodman ML et al. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst. Rev. 4, CD003448 (2006). (Pubitemid 46841255)
21. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J. Pain Symptom Manage. 23, 48-53 (2002). (Pubitemid 34093880)
22. Sykes NP. Oral naloxone in opioid-associated constipation. Lancet 337, 1475 (1991).
23. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat. Med. 10, 135-144 (1996).
24. McNicol ED, Boyce D, Schumann R et al. μ-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst. Rev. 2, CD006332 (2008). (Pubitemid 351807375)
25. Joint Formulary Committee. British National Formulary (57th Edition). British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK (2009).
26. GlaxoSmithKline. Alvimopan: summary of product characteristics.
27. Paulson DM, Kennedy DT, Donovick RA et al. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J. Pain 6, 184-192 (2005).
28. Webster L, Jansen JP, Peppin J et al. Alvimopan, a peripherally acting μ-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137, 428-440 (2008).
29. Saad R, Chey WD. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev. Gastroenterol. Hepatol. 2, 497-508 (2008).
30. Johanson JF, Morton D, Geenen J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103, 170-177 (2008).
31. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat. Med. 12, 375-382 (1998).
32. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N. Engl. J. Med. 358, 2332-2343 (2008). •• Key, pivotal study. (Pubitemid 351749157)
33. Campora E, Merlini L, Pace M et al. The incidence of narcotic-induced emesis. J. Pain Symptom Manage. 6, 428-430 (1991).
34. Aparasu R, McCoy RA, Weber C et al. Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life. J. Pain Symptom Manage. 18, 280-288 (1999). (Pubitemid 29469706)
35. Foss JF, Yuan CS, Roizen MF et al. Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother. Pharmacol. 42, 287-291 (1998).
36. Foss JF, Bass AS, Goldberg LI. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. J. Clin. Pharmacol. 33, 747-751 (1993).
37. Moerman I, Franck P, Camu F. Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences. Acta Anaesthesiol. Belg. 46, 127-132 (1995). (Pubitemid 26157587)
38. Foss JF, O'Connor MF, Yuan CS et al. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J. Clin. Pharmacol. 37, 25-30 (1997).
39. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin. Pharmacol. Ther. 59, 469-475 (1996). (Pubitemid 26151630)
40. Yuan CS, Foss JF, O'Connor M et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283, 367-372 (2000). (Pubitemid 30051755)
41. Viscusi ER, Rathmell JP, Fichera A et al. Methylnaltrexone bromide administered postoperatively to patients following segmental colectomy may accelerate bowel recovery and hospital discharge without affecting opioid analgesia. Presented at: Gastrointestinal Cancers Symposium 2007. Orlando, FL, USA, 19-21 January 2007.
42. Slatkin N, Thomas J, Lipman AG et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J. Support. Oncol. 7, 39-46 (2009). • Second pivotal study.
43. Yuan CS, Foss JF, Osinski J et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin. Pharmacol. Ther. 61, 467-475 (1997). (Pubitemid 27195949)
44. Kraft MD. Methylnaltrexone, a new peripherally acting μ-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin. Investig. Drugs 17, 1365-1377 (2008).
45. Rosow CE, Gomery P, Chen TY et al. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin. Pharmacol. Ther. 82, 48-53 (2007). (Pubitemid 46944195)
46. Yuan CS, Foss JF, O'Connor M et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend. 52, 161-165 (1998). (Pubitemid 28529495)
47. Ho WZ, Guo CJ, Yuan CS et al. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J. Pharmacol. Exp. Ther. 307, 1158-1162 (2003).
48. Press release: GlaxoSmithKline and Adolor report top line results from Phase 3 studies of Alvimopan (Entereg/Entrareg®). London, UK; PA, USA, 5 September (2006) www.internationalbiotrust.com/press-releases/new/5-Sept-06.pdf (Accessed 25 March 2009)
49. Press release: GSK and Adolor announce preliminary results from Phase 3 Safety study of Alvimopan (Entereg/Entrareg). London, UK; PA, USA, 9 April (2007) www.gsk.com/media/ pressreleases/2007/2007-04-09-GSK1012.htm (Accessed 25 March 2009)
50. Adolor Corporation (ADLR) to stop development of bowel dysfunction drug. Biospace, 18 December (2008) www.biospace.com/news-story.aspx?NewsEntityId= 120878 (Accessed 25 March 2009)
51. Van Paaschen. Results from a Phase 1, double blind, randomized, placebo-controlled, multiple-dose study evaluating the safety, tolerability and pharmacokinetics of oral doses of NKTR-118 www.nektar.com/pdf/pipeline/NKTR-118/ NKTR-118-Phase-1-APS- Poster-20080507.pdf (Accessed 25 March 2009)
52. Nektar R&D Pipeline: Products in Development - Clinical Trials Information www.nektar.com/product-pipeline/clinical-trials.html (Accessed 25 March 2009)
53. ClinicalTrials.gov: lubiprostone search results www.clinicaltrials.gov/ ct2/results?term=lubiprostone (Accessed 25 March 2009)
54. Sucampo Pharmaceuticals. News release: sucampo completes enrollment in Phase 3 pivotal studies of oral lubiprostone to treat opioid-induced bowel dysfunction Phase 3 efficacy data expected in summer 2009. MD, USA, 2 December (2008) http://investor.sucampo.com/phoenix. zhtml?c=201197&p= irolnewsArticle& ID=1231763&highlight=(Accessed 25 March 2009)
55. Wyeth. Relistor: summary of product characteristics www.wyeth.com/ content/showlabeling.asp?id=499 (Accessed 16 December 2008)
56. EMEA: the European Medicines Agency. Assessment report for Relistor www.emea.europa.eu/humandocs/PDFs/EPAR/relistor/H-870-en6.pdf (Accessed 16 December 2008) •• Excellent independent evaluation.
57. FDA-approved Risk Evaluation and Mitigation Strategies (REMS) www.fda.gov/cder/drug/DrugSafety/REMS.htm (Accessed 25 March 2009)
58. Press release: Wyeth and Progenics announce relistor receives Canadian marketing approval. PA, USA; NY, USA, 1 April 2008 www.wyeth.com/news/archive? nav=display&navTo=/wyeth-html/home/news/ pressreleases/2008/1207054025120. html (Accessed 25 March 2009)
59. ClinicalTrials.gov www.clinicaltrials.gov (Accessed 24 June 2009)
60. Press release: Wyeth and Progenics announce preliminary clinical trial results for Relistor oral and intravenous formulations. PA, USA; NY, USA, 22 May (2008) www.wyeth.com/news/archive?nav=display&navTo=/wyeth-html/home/news/ pressreleases/2008/1211465152818.html (Accessed 25 March 2009)
61. Progenics Pharmaceuticals, Inc. www.progenics.com (Accessed 25 June 2009)
62. Press release: Wyeth and Progenics provide update on Phase 3 clinical trial of intravenous methylnaltrexone for postoperative ileus. PA, USA; NY, USA, 12 March (2008) www.drugs.com/clinical-trials/wyethprogenics-provide-update- phase-3-clinicaltrial-intravenous-methylnaltrexonepostoperative- 3562.html (Accessed 25 March 2009)